MedTrace Logo

Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine

NCT02109497 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-04-29

Study results available
· View outcomes & findings →

Summary

This study is designed to determine the pharmacokinetic (PK) profile of a single oral dose of caffeine and the effects that PBT2 has on the metabolism of caffeine in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

PBT2

PBT2 250 mg administered

Sponsors & Collaborators

  • Prana Biotechnology Limited

    lead INDUSTRY

Principal Investigators

  • Caroline Herd · Prana Biotechnology

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-06-30
Completion
2014-07-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02109497 on ClinicalTrials.gov